Anti-coagulation and anti-platelet therapy for heart disease

Novel agents for anti-platelet therapy

Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and tirofiban) have demonstrated good clinical benefits an...

Anti-platelet therapy for Acute Coronary Syndrome

The term ‘Acute Coronary Syndrome’ (ACS) refers to a range of acute myocardial ischaemic states which include unstable angina, non ST segment elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI). Despite significant advances in the diagnosis and management, ACS remains a significant global problem with very high mortality and morbidity. The pathogeneti...

Anti-Coagulation During Pregnancy in Women with Mechanical Heart Valves: A Prospective Study

Anti-platelet therapy: ADP receptor antagonists

The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists th...

Anti-coagulation therapy following coronary endarterectomy in patient with coronary artery bypass graft

Background: Since there is a lack of research on postoperative anticoagulation protocol in patients undergoing coronary artery bypass graft (CABG) / coronary endarterectomy (CE), we recommend a new protocol for anticoagulation in these patients. Methods: In this double-blind randomized clinical trial study, 52 patients undergoing CABG / CE entered the study and were divided into two groups. In...